Genetic and environmental influences on total plasma homocysteine and its role in coronary artery disease risk

Atherosclerosis

Volumn 222, Issue 1, 2012, Pages 180-186

  Ghassibe Sabbagh, Michella ^a   Platt, Daniel E ^b   Youhanna, Sonia ^a   Abchee, Antoine B ^c   Stewart, Krista ^d   Badro, Danielle A ^a   Haber, Marc ^a   Salloum, Angelique K ^a   Douaihy, Bouchra ^a   el Bayeh, Hamid ^a   Othman, Raed ^e   Shasha, Nabil ^e   Kibbani, Samer ^e   Chammas, Elie ^a   Milane, Aline ^a   Nemr, Rita ^a   Kamatani, Yoichiro ^f   Hager, Jörg ^g   Cazier, Jean Baptiste ^h   Gauguier, Dominique ^h,i   Zalloua, Pierre A ^a,j   more..

^a LEBANESE AMERICAN UNIVERSITY   (Lebanon)

^b IBM T J WATSON RESEARCH CENTER   (United States)

^c AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^d UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^e RAFIC HARIRI UNIVERSITY HOSPITAL   (Lebanon)

^f FONDATION JEAN DAUSSET CEPH   (France)

^g CENTRE NATIONAL DE GÉNOTYPAGE   (France)

^h UNIVERSITY OF OXFORD   (United Kingdom)

ⁱ CENTRE DE RECHERCHE DES CORDELIERS   (France)

^j HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

more..

Author keywords

Coronary artery disease (CAD); Diuretics; Homocysteine; Hyperhomocysteinemia; Hypertension; Lebanese population

Indexed keywords

ANGIOTENSIN II ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HOMOCYSTEINE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); ORGANIC ANION TRANSPORTER 2; VASODILATOR AGENT;

ADULT; ALCOHOL CONSUMPTION; AMINO ACID BLOOD LEVEL; ARTICLE; CARDIOVASCULAR RISK; COFFEE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; CORRELATION ANALYSIS; DISEASE ASSOCIATION; ENVIRONMENTAL FACTOR; FAMILY HISTORY; FEMALE; GENETIC ASSOCIATION; HEART CATHETERIZATION; HEART INJURY; HEREDITY; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERLIPIDEMIA; HYPERTENSION; LEBANON; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING;

ADULT; AGED; CONSTRICTION, PATHOLOGIC; CORONARY ARTERY DISEASE; DIURETICS; FEMALE; GENE-ENVIRONMENT INTERACTION; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; HYPERTENSION; LEBANON; LOGISTIC MODELS; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; ORGANIC ANION TRANSPORTERS; POLYMORPHISM, GENETIC; RISK FACTORS;

EID: 84859877872     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2012.02.035     Document Type: Article

References (30)

1. Yusuf S., Hawken S., Ounpuu S., et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004, 364(9438):937-952.
2. Scheuner M.T., Whitworth W.C., McGruder H., Yoon P.W., Khoury M.J. Familial risk assessment for early-onset coronary heart disease. Genetics in Medicine: Official Journal of the American College of Medical Genetics 2006, 8(8):525-531.
3. Pisciotta L., Cortese C., Gnasso A., et al. Serum homocysteine, methylenetetrahydrofolate reductase gene polymorphism and cardiovascular disease in heterozygous familial hypercholesterolemia. Atherosclerosis 2005, 179(2):333-338.
4. Manolescu B.N., Oprea E., Farcasanu I.C., Berteanu M., Cercasov C. Homocysteine and vitamin therapy in stroke prevention and treatment: a review. Acta Biochimica Polonica 2010, 57(4):467-477.
5. Morrow L.E., Grimsley E.W. Long-term diuretic therapy in hypertensive patients: effects on serum homocysteine, vitamin B6, vitamin B12, and red blood cell folate concentrations. Southern Medical Journal 1999, 92(9):866-870.
6. Saposnik G., Ray J.G., Sheridan P., McQueen M., Lonn E. Heart outcomes prevention evaluation I: Homocysteine-lowering therapy and stroke risk, severity, and disability: additional findings from the HOPE 2 trial. Stroke; A Journal of Cerebral Circulation 2009, 40(4):1365-1372.
7. Clarke R., Halsey J., Lewington S., et al. Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality: meta-analysis of 8 randomized trials involving 37 485 individuals. Archives of Internal Medicine 2010, 170(18):1622-1631.
8. Dierkes J., Luley C., Westphal S. Effect of lipid-lowering and anti-hypertensive drugs on plasma homocysteine levels. Journal of Vascular Health and Risk Management 2007, 3(1):99-108.
9. Kluijtmans L.A., Whitehead A.S. Methylenetetrahydrofolate reductase genotypes and predisposition to atherothrombotic disease; evidence that all three MTHFR C677T genotypes confer different levels of risk. European Heart Journal 2001, 22(4):294-299.
10. Smulders Y.M., Blom H.J. The homocysteine controversy. Journal of Inherited Metabolic Disease 2011, 34(1):93-99.
11. Stehouwer C.D.A., van Guldener C. Homocysteine-lowering treatment: an overview. Expert Opinion on Pharmacotherapy 2001, 2(9):1449-1460.
12. Naruszewicz M., Jankowska E.A., Zymlinski R., et al. Hyperhomocysteinemia in patients with symptomatic chronic heart failure: prevalence and prognostic importance-pilot study. Atherosclerosis 2007, 194(2):408-414.
13. Wu Y., Yang L., Zhong L. Decreased serum levels of thioredoxin in patients with coronary artery disease plus hyperhomocysteinemia is strongly associated with the disease severity. Atherosclerosis 2010, 212(1):351-355.
14. Abchee A., Puzantian H., Azar S.T., et al. Predictors of coronary artery disease in the Lebanese population. Thrombosis Research 2006, 117(6):631-637.
15. Youhanna S., Platt D.E., Rebeiz A., et al. Parental consanguinity and family history of coronary artery disease strongly predict early stenosis. Atherosclerosis 2010, 212(2):559-563.
16. Kelemen L.E., Anand S.S., Hegele R.A., et al. Associations of plasma homocysteine and the methylenetetrahydrofolate reductase C677T polymorphism with carotid intima media thickness among South Asian, Chinese and European Canadians. Atherosclerosis 2004, 176(2):361-370.
17. Laraqui A., Allami A., Carrie A., et al. Influence of methionine synthase (A2756G) and methionine synthase reductase (A66G) polymorphisms on plasma homocysteine levels and relation to risk of coronary artery disease. Acta Cardiologica 2006, 61(1):51-61.
18. Brilakis E.S., Berger P.B., Ballman K.V., Rozen R. Methylenetetrahydrofolate reductase (MTHFR) 677C>T and methionine synthase reductase (MTRR) 66A>G polymorphisms: association with serum homocysteine and angiographic coronary artery disease in the era of flour products fortified with folic acid. Atherosclerosis 2003, 168(2):315-322.
19. Jacques P.F., Bostom A.G., Selhub J., et al. Effects of polymorphisms of methionine synthase and methionine synthase reductase on total plasma homocysteine in the NHLBI Family Heart Study. Atherosclerosis 2003, 166(1):49-55.
20. Vinukonda G., Shaik Mohammad N., Md Nurul Jain J., Prasad Chintakindi K., Rama Devi Akella R. Genetic and environmental influences on total plasma homocysteine and coronary artery disease (CAD) risk among South Indians. Clinica Chimica Acta 2009, 405(1-2):127-131.
21. Wang F., Xu C.Q., He Q., et al. Genome-wide association identifies a susceptibility locus for coronary artery disease in the Chinese Han population. Nature Genetics 2011, 43(4):345-349.
22. Humphries K.H., Gill S. Risks and benefits of hormone replacement therapy: the evidence speaks. CMAJ: Canadian Medical Association Journal 2003, 168(8):1001-1010.
23. Köz C., Celebi H., Yokuşoĝlu M., et al. The relation between coronary lesion distribution and risk factors in young adults. Anadolu Kardiyoloji Dergisi 2009, 9(2):91-95.
24. Sundstrom J., Sullivan L., D'Agostino R.B., et al. Plasma homocysteine, hypertension incidence, and blood pressure tracking: the Framingham Heart Study. Hypertension 2003, 42(6):1100-1105.
25. Ustundag S., Arikan E., Sen S., Esgin H., Ciftci S. The relationship between the levels of plasma total homocysteine and insulin resistance in uncomplicated mild-to-moderate primary hypertension. Journal of Human Hypertension 2006, 20(5):379-381.
26. Link E., Parish S., Armitage J., et al. SLCO1B1 variants and statin-induced myopathy-a genomewide study. The New England Journal of Medicine 2008, 359(8):789-799.
27. Johnson A.D., Kavousi M., Smith A.V., et al. Genome-wide association meta-analysis for total serum bilirubin levels. Human Molecular Genetics 2009, 18(14):2700-2710.
28. Zhang M., Ma H., Wang B.S., Zhao Y.Z. Angiotensin II type 2 receptor gene polymorphisms and cardioprotective role in essential hypertension. Heart and Vessels 2006, 21(2):95-101.
29. Westphal S., Rading A., Luley C., Dierkes J. Antihypertensive treatment and homocysteine concentrations. Metabolism 2003, 52(3):261-263.
30. Mager A., Orvin K., Koren-Morag N., et al. Impact of homocysteine-lowering vitamin therapy on long-term outcome of patients with coronary artery disease. The American Journal of Cardiology 2009, 104(6):745-749.